Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (299,753) | (305,700) |
| Proceeds from maturities and sales of marketable securities | 508,256 | 508,894 |
| Payments associated with license agreement | (25,000) | (10,000) |
| Purchases of property and equipment | (1,981) | (1,641) |
| Net cash provided by investing activities | 181,522 | 191,553 |
| Financing activities | ||
| Net proceeds from stock option exercises and employee stock purchase plan | 5,227 | 1,684 |
| Net cash provided by financing activities | 5,227 | 1,684 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's capex?
- Agios Pharmaceuticals (AGIO) reported capex of $1.21M in Q2 2026.
- How has Agios Pharmaceuticals's capex changed year-over-year?
- Agios Pharmaceuticals's capex increased by 38.5% year-over-year, from $875K to $1.21M.
- What is the long-term trend for Agios Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's capex has grown at a -7.0% compound annual growth rate (CAGR), from $5.76M to $4.32M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Agios Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude